National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China: Modelled estimates for 2010-17.

Autor:	Lai X; China Center for Health Development Studies, Peking University, Beijing, China.; Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China., Wahl B; Johns Hopkins India, Lucknow, India.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA., Yu W; National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China., Xu T; Department of Health Policy and Management, School of Public Health, Capital Medical University, Beijing, China., Zhang H; China Center for Health Development Studies, Peking University, Beijing, China.; Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China., Garcia C; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA., Qin Y; Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China., Guo Y; Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China., Yin Z; National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China., Knoll MD; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA., Fang H; China Center for Health Development Studies, Peking University, Beijing, China.; Peking University Health Science Center-Chinese Center for Disease Control and Prevention Joint Research Center for Vaccine Economics, Peking University, Beijing, China.; Key Laboratory of Reproductive Health, National Health Commission of the People's Republic of China, Beijing, China.
Jazyk:	angličtina
Zdroj:	The Lancet regional health. Western Pacific [Lancet Reg Health West Pac] 2022 Mar 16; Vol. 22, pp. 100430. Date of Electronic Publication: 2022 Mar 16 (Print Publication: 2022).
DOI:	10.1016/j.lanwpc.2022.100430
Abstrakt:	Background: Vaccination against Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib) is not included in China's national immunization programme. To inform China's immunization polices, we estimated annual national, regional, and provincial childhood mortality and morbidity attributable to pneumococcus and Hib in 2010-17. Methods: We estimated proportions of pneumonia and meningitis deaths and cases attributable to pneumococcus and Hib using evidence from vaccine clinical trials and surveillance studies of bacterial meningitis and pathogen-specific case fatality ratios (CFR). Then we applied the proportions to model provincial-level pneumonia cases and deaths, meningitis deaths and meningitis CFR in children aged 1-59 months, accounting for vaccine coverage. Non-pneumonia, non-meningitis (NPNM) invasive disease cases were derived by applying NPNM meningitis ratios to meningitis estimates. Findings: In 2010-17, annual pneumococcal deaths fell by 49% from 15 600 (uncertainty range: 10 800-17 300) to 8 000 (5 500-8 900), and Hib deaths fell by 56% from 6 500 (4 500-8 800) to 2 900 (2 000-3 900). Severe pneumococcal and Hib cases decreased by 16% to 218 200 (161 500-252 200) in 2017 and 29% to 49 900 (29 000-99 100). Estimated 2017 national three-dose coverage in private market was 1·3% for PCV and 33·4% for Hib vaccine among children aged 1-59 months. Provinces in the west region had the highest disease burden. Interpretation: Childhood mortality and morbidity attributable to pneumococcal and Hib has decreased in China, but still substantially varied by region and province. Higher vaccine coverage could further reduce disease burden. Funding: Bill & Melinda Gates Foundation. Competing Interests: HF reports grants from the Bill & Melinda Gates Foundation and Sanofi Pasteur. BW reports grants from the Bill & Melinda Gates Foundation. MDK reports grants from the Bill & Melinda Gates Foundation, Pfizer and Gavi Alliance, and personal fees from Merck. CG reports grants from the Bill & Melinda Gates Foundation and Pfizer, and personal fees from Merck. All other authors declare no competing interests. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu